Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus SODIUM SULAMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus SODIUM SULAMYD.
ALTABAX vs SODIUM SULAMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Sodium sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
1-2 drops of 10% or 15% solution into affected eye(s) every 2-3 hours initially, tapered as infection resolves; ophthalmic ointment: apply 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
7-13 hours (prolonged in renal impairment; in anuria up to 22-50 hours)
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal excretion of unchanged drug (approximately 70-100%) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic